Cargando…
Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology?
INTRODUCTION: The Notch intracellular domain (NICD) and its ligands Jagged-1(Jag1), Delta-like ligand (DLL-3) and DLL4 play an important role in neoangiogenesis. Previous studies suggest a correlation between the tissue levels of NICD and response to therapy with bevacizumab in colorectal cancer (CR...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011088/ https://www.ncbi.nlm.nih.gov/pubmed/36925919 http://dx.doi.org/10.3389/fonc.2023.1132564 |
_version_ | 1784906309634621440 |
---|---|
author | Negri, Francesca Bottarelli, Lorena Pedrazzi, Giuseppe Maddalo, Michele Leo, Ludovica Milanese, Gianluca Sala, Roberto Lecchini, Michele Campanini, Nicoletta Bozzetti, Cecilia Zavani, Andrea Di Rienzo, Gianluca Azzoni, Cinzia Silini, Enrico Maria Sverzellati, Nicola Gaiani, Federica de’ Angelis, Gian Luigi Gnetti, Letizia |
author_facet | Negri, Francesca Bottarelli, Lorena Pedrazzi, Giuseppe Maddalo, Michele Leo, Ludovica Milanese, Gianluca Sala, Roberto Lecchini, Michele Campanini, Nicoletta Bozzetti, Cecilia Zavani, Andrea Di Rienzo, Gianluca Azzoni, Cinzia Silini, Enrico Maria Sverzellati, Nicola Gaiani, Federica de’ Angelis, Gian Luigi Gnetti, Letizia |
author_sort | Negri, Francesca |
collection | PubMed |
description | INTRODUCTION: The Notch intracellular domain (NICD) and its ligands Jagged-1(Jag1), Delta-like ligand (DLL-3) and DLL4 play an important role in neoangiogenesis. Previous studies suggest a correlation between the tissue levels of NICD and response to therapy with bevacizumab in colorectal cancer (CRC). Another marker that may predict outcome in CRC is radiomics of liver metastases. The aim of this study was to investigate the expression of NICD and its ligands and the role of radiomics in the selection of treatment-naive metastatic CRC patients receiving bevacizumab. METHODS: Immunohistochemistry (IHC) for NICD, Jag1 and E-cadherin was performed on the tissue microarrays (TMAs) of 111 patients with metastatic CRC treated with bevacizumab and chemotherapy. Both the intensity and the percentage of stained cells were evaluated. The absolute number of CD4+ and CD8+ lymphocytes was counted in three different high-power fields and the mean values obtained were used to determine the CD4/CD8 ratio. The positivity of tumor cells to DLL3 and DLL4 was studied. The microvascular density (MVD) was assessed in fifteen cases by counting the microvessels at 20x magnification and expressed as MVD score. Abdominal CT scans were retrieved and imported into a dedicated workstation for radiomic analysis. Manually drawn regions of interest (ROI) allowed the extraction of radiomic features (RFs) from the tumor. RESULTS: A positive association was found between NICD and Jag1 expression (p < 0.001). Median PFS was significantly shorter in patients whose tumors expressed high NICD and Jag1 (6.43 months vs 11.53 months for negative cases; p = 0.001). Those with an MVD score ≥5 (CD31-high, NICD/Jag1 positive) experienced significantly poorer survival. The radiomic model developed to predict short and long-term survival and PFS yielded a ROC-AUC of 0.709; when integrated with clinical and histopathological data, the integrated model improved the predictive score (ROC-AUC of 0.823). DISCUSSION: These results show that high NICD and Jag1 expression are associated with progressive disease and early disease progression to anti VEGF-based therapy; the preliminary radiomic analyses show that the integration of quantitative information with clinical and histological data display the highest performance in predicting the outcome of CRC patients. |
format | Online Article Text |
id | pubmed-10011088 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100110882023-03-15 Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology? Negri, Francesca Bottarelli, Lorena Pedrazzi, Giuseppe Maddalo, Michele Leo, Ludovica Milanese, Gianluca Sala, Roberto Lecchini, Michele Campanini, Nicoletta Bozzetti, Cecilia Zavani, Andrea Di Rienzo, Gianluca Azzoni, Cinzia Silini, Enrico Maria Sverzellati, Nicola Gaiani, Federica de’ Angelis, Gian Luigi Gnetti, Letizia Front Oncol Oncology INTRODUCTION: The Notch intracellular domain (NICD) and its ligands Jagged-1(Jag1), Delta-like ligand (DLL-3) and DLL4 play an important role in neoangiogenesis. Previous studies suggest a correlation between the tissue levels of NICD and response to therapy with bevacizumab in colorectal cancer (CRC). Another marker that may predict outcome in CRC is radiomics of liver metastases. The aim of this study was to investigate the expression of NICD and its ligands and the role of radiomics in the selection of treatment-naive metastatic CRC patients receiving bevacizumab. METHODS: Immunohistochemistry (IHC) for NICD, Jag1 and E-cadherin was performed on the tissue microarrays (TMAs) of 111 patients with metastatic CRC treated with bevacizumab and chemotherapy. Both the intensity and the percentage of stained cells were evaluated. The absolute number of CD4+ and CD8+ lymphocytes was counted in three different high-power fields and the mean values obtained were used to determine the CD4/CD8 ratio. The positivity of tumor cells to DLL3 and DLL4 was studied. The microvascular density (MVD) was assessed in fifteen cases by counting the microvessels at 20x magnification and expressed as MVD score. Abdominal CT scans were retrieved and imported into a dedicated workstation for radiomic analysis. Manually drawn regions of interest (ROI) allowed the extraction of radiomic features (RFs) from the tumor. RESULTS: A positive association was found between NICD and Jag1 expression (p < 0.001). Median PFS was significantly shorter in patients whose tumors expressed high NICD and Jag1 (6.43 months vs 11.53 months for negative cases; p = 0.001). Those with an MVD score ≥5 (CD31-high, NICD/Jag1 positive) experienced significantly poorer survival. The radiomic model developed to predict short and long-term survival and PFS yielded a ROC-AUC of 0.709; when integrated with clinical and histopathological data, the integrated model improved the predictive score (ROC-AUC of 0.823). DISCUSSION: These results show that high NICD and Jag1 expression are associated with progressive disease and early disease progression to anti VEGF-based therapy; the preliminary radiomic analyses show that the integration of quantitative information with clinical and histological data display the highest performance in predicting the outcome of CRC patients. Frontiers Media S.A. 2023-02-28 /pmc/articles/PMC10011088/ /pubmed/36925919 http://dx.doi.org/10.3389/fonc.2023.1132564 Text en Copyright © 2023 Negri, Bottarelli, Pedrazzi, Maddalo, Leo, Milanese, Sala, Lecchini, Campanini, Bozzetti, Zavani, Di Rienzo, Azzoni, Silini, Sverzellati, Gaiani, de’ Angelis and Gnetti https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Negri, Francesca Bottarelli, Lorena Pedrazzi, Giuseppe Maddalo, Michele Leo, Ludovica Milanese, Gianluca Sala, Roberto Lecchini, Michele Campanini, Nicoletta Bozzetti, Cecilia Zavani, Andrea Di Rienzo, Gianluca Azzoni, Cinzia Silini, Enrico Maria Sverzellati, Nicola Gaiani, Federica de’ Angelis, Gian Luigi Gnetti, Letizia Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology? |
title | Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology? |
title_full | Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology? |
title_fullStr | Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology? |
title_full_unstemmed | Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology? |
title_short | Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology? |
title_sort | notch-jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: a glance to radiomics or back to physiopathology? |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011088/ https://www.ncbi.nlm.nih.gov/pubmed/36925919 http://dx.doi.org/10.3389/fonc.2023.1132564 |
work_keys_str_mv | AT negrifrancesca notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT bottarellilorena notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT pedrazzigiuseppe notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT maddalomichele notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT leoludovica notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT milanesegianluca notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT salaroberto notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT lecchinimichele notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT campanininicoletta notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT bozzetticecilia notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT zavaniandrea notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT dirienzogianluca notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT azzonicinzia notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT silinienricomaria notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT sverzellatinicola notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT gaianifederica notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT deangelisgianluigi notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology AT gnettiletizia notchjagged1signalingandresponsetobevacizumabtherapyinadvancedcolorectalcanceraglancetoradiomicsorbacktophysiopathology |